Home Depot Builds O...
Health Care: Drugs
Arrowhead Research Corporation (ARWR: NASDAQ)
$2.14 0.01 | 0.47%
05/21/13 - 09:29 AM ET
Company Income Statement
| Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
| Sales | 146.88K | 296.14K | 620.10K | 3.77M |
| Cost of Sales | 0.00 | 0.00 | -339.06K | -607.51K |
| Gross Operating Profit | 146.88K | 296.14K | 959.16K | 4.38M |
| Selling, General, and Administrative Expenses | 14.10M | 5.23M | 8.00M | 14.14M |
| Research & Development | 5.39M | 3.28M | 1.11M | 8.97M |
| Operating Income before D & A (EBITDA) | -19.34M | -8.21M | -8.15M | -18.73M |
| Depreciation & Amortization | 1.76M | 260.04K | 654.69K | 994.60K |
| Interest Income | 35.97K | 86.53K | 0.00 | 0.00 |
| Other Income - Net | -817.24K | -255.01K | 1.69M | 96.88K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -22.12M | -8.80M | -7.34M | -19.16M |
| Interest Expense | 0.00 | 0.00 | 48.02K | 150.89K |
| Pre-Tax Income | -22.12M | -8.80M | -7.38M | -19.31M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | -984.80K | -363.51K | -1.18M | -60.00 |
| Net Income From Continuing Operations | -22.11M | -8.79M | -7.38M | -19.31M |
| Net Income From Discontinued Operations | -80.00 | 5.29M | 427.34K | 0.00 |
| Net Income From Total Operations | -22.11M | -3.49M | -6.96M | -19.31M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -21.13M | -3.13M | -5.77M | -19.31M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-22.11M | -8.79M | -7.38M | -19.31M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -22.11M | -8.79M | -7.38M | -19.31M |
| Basic EPS from Continuing Ops. | -1.90 | -1.18 | -1.00 | -4.30 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.74 | 0.10 | 0.00 |
| Basic EPS from Total Operations | -1.90 | -0.44 | -0.90 | -4.30 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.90 | -0.44 | -0.90 | -4.30 |
| Basic Normalized Net Income/Share | -1.90 | -1.18 | -1.00 | -4.30 |
| EPS fr Continuing Ops. | -1.90 | -1.08 | -1.00 | -4.30 |
| EPS fr Discontinued Ops | 0.00 | 0.68 | 0.10 | 0.00 |
| EPS fr Total Ops. | -1.90 | -0.40 | -0.90 | -4.30 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.90 | -0.40 | -0.90 | -4.30 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.90 | -1.08 | -1.00 | -4.30 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ARWR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Usertest1123
- ContributorStocks Under-$10 Setting Up...
- UserKJP 2012 Carbon Flash Fund
- Contributor8 Penny Stocks Get Delistin...
- UserWilliam T Blanchard - Medical
- UserCaroline
- UserSimon $9000
- Usertreneehill's pennies
Latest ARWR Headlines from TheStreet
- 5 Health Care Stocks Under $10 to Watch 04.30.13 | 02:04 pm
- 5 Stocks Under $10 Set to Soar 02.28.13 | 01:02 pm
- 4 Biotech Stocks Under $10 Moving Higher 02.20.13 | 09:02 pm
- 5 Stocks Under $10 Set to Trade Higher in November 11.01.12 | 01:11 pm
- Arrowhead's Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript) 08.14.12 | 09:08 pm
- Arrowhead Research Corporation's CEO Discusses F3Q12 Results - Earnings Call Transcript 08.13.12 | 08:08 pm
- Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript) 05.08.12 | 12:05 am
- 6 Stocks Hitting New 52-Week Highs 11.10.11 | 01:11 pm
- 8 Penny Stocks Get Delisting Warning 01.04.11 | 07:01 am
- Arrowhead Research CEO Discusses F4Q2010 Results  Earnings Call Transcript 12.22.10 | 09:12 pm
Press Releases for ARWR
- Arrowhead Induces 90% Reduction In Hepatitis B Antigens In Chimpanzee With Chronic Infection: Data Follow Previous Report Of Reduction In Viral DNA - Business Wire 03.25.13 | 07:03 am
- Arrowhead RNAi Candidate ARC-520 Induces Greater Than 90% Reduction In Circulating HBV DNA In Chimpanzee With Chronic Hepatitis B - Business Wire 03.14.13 | 07:03 am
- Arrowhead To Host Analyst Event In New York To Discuss RNAi-based Hepatitis B Candidate ARC-520 - Business Wire 03.07.13 | 07:03 am
- Arrowhead Receives Notice Of Patent Allowance For New Protease Sensitive Masking Chemistry For DPC SiRNA Delivery System - Business Wire 02.28.13 | 07:02 am
- Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus - Business Wire 02.26.13 | 09:02 am
- Arrowhead Reports Fiscal 2013 First Quarter Financial Results - Business Wire 02.13.13 | 04:02 pm
- Lifshitz Law Firm Announces Investigation Of Arrowhead Research Corp., MEI Pharma, Inc., Park City Group, Inc., And The Toro Company - PR Newswire 02.07.13 | 05:02 pm
- Arrowhead To Report Fiscal 2013 First Quarter Financial Results - Business Wire 02.06.13 | 07:02 am
- Arrowhead To Present At Upcoming Scientific Conferences - Business Wire 02.01.13 | 07:02 am
- Arrowhead Announces Pricing Of A Public Offering Of Common Stock And Warrants - Business Wire 01.25.13 | 09:01 am
Partner Headlines for ARWR
- Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency - Benzinga 10.16.12 | 09:10 am
- Arrowhead Sells 2.3M Shares, 1.7M Warrants for $6.2M - Benzinga 08.13.12 | 09:08 am
- Anti-Obesity Drug CAUSES Trouble for Arrowhead and 4 Stocks that Have Hit 52-Week Lows - Wall St. Cheat Sheet 06.27.12 | 10:06 am
- 4 Smaller Alternatives to Big Pharma Obesity Treatments - Benzinga 05.25.12 | 01:05 pm
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Arrowhead Reports Q1 EPS of $(0.02) - Benzinga 02.10.11 | 04:02 pm
- UPDATE 1-Arrowhead co, Smith & Nephew to make cartilage product - Reuters 10.18.10 | 08:10 am
